GNR-051 / Generium - LARVOL DELTA

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: AO GENERIUM | Trial completion date: Jun 2024 ➔ Jan 2025

Metastases • Trial completion date • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: AO GENERIUM | Recruiting ➔ Active, not recruiting | Trial primary completion date: Apr 2024 ➔ Nov 2022

Enrollment closed • Metastases • Trial primary completion date • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-1

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: AO GENERIUM; Trial completion date: Nov 2024 ➔ Jun 2024; Trial primary completion date: Nov 2024 ➔ Apr 2024

Clinical • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-1

A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: AO GENERIUM

Clinical • New P1 trial • Genito-urinary Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor